EAM Global Investors’s BridgeBio Pharma BBIO Stock Holding History

EAM Global Investors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-109,392	Closed	-$4.72M	–	20
2025 Q2	$4.72M	Buy	+109,392	New	+$3.98M	1.22%	46
2024 Q1	–	Sell	-118,138	Closed	-$4.77M	–	95
2023 Q4	$4.77M	Sell	118,138 -23,372	-17%	-$702K	1.15%	25
2023 Q3	$3.73M	Sell	141,510 -81,724	-37%	-$2.32M	1.01%	43
2023 Q2	$3.84M	Hold	223,234	–	–	1.13%	54
2023 Q1	$3.7M	Buy	+223,234	New	+$2.6M	1.04%	58

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Global Investors's BBIO Position: Q3 2025 in Review

EAM Global Investors sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 109,392 shares — an estimated $4.72M sold.

EAM Global Investors first reported a position in BBIO in Q1 2023 and held it in 5 quarters. The position peaked at $4.77M in Q4 2023. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

EAM Global Investors reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
EAM Global Investors sold 109,392 BridgeBio Pharma shares in Q3 2025, an estimated $4.72M.
EAM Global Investors first reported a position in BridgeBio Pharma in Q1 2023 and held it in 5 quarters.
EAM Global Investors's BridgeBio Pharma position peaked at $4.77M in Q4 2023.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on EAM Global Investors's 13F filing for Q3 2025, filed 14 Nov 2025.